Decreased effectiveness of the influenza A(H1N1) pdm09 strain in live attenuated influenza vaccines: An observational bias or a technical challenge?

Eurosurveillance

Volumn 21, Issue 38, 2016, Pages

  Penttinen, Pasi M ^a   Friede, M H ^b  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; RECOMBINANT VACCINE; SIALIDASE; LIVE VACCINE;

ADOLESCENT; CASE CONTROL STUDY; CHILD; COMPARATIVE EFFECTIVENESS; DISEASE TRANSMISSION; EDITORIAL; HEALTH EDUCATION; HUMAN; IMMUNIZATION; INFLUENZA A; INFLUENZA A (H1N1); OBSERVATIONAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS STRAIN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN;

HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED;

EID: 84990888749     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.38.30350     Document Type: Editorial

References (22)

1. Rudenko L, Isakova-Sivak I. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines. 2015; 14(3): 395-412. DOI: 10.1586/14760584.2015.979159 PMID: 25555687
2. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep. 2016; 65(5): 1-54. DOI: 10.15585/mmwr.rr6505a1 PMID: 27560619
3. European Medicines Agency (EMA). European public assessment report for Fluenz. London: EMA. [Accessed 22 Sep 2016]. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Summary_for_the_public/ human/001101/WC500103712.pdf
4. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al., CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children.N Engl J Med. 2007; 356(7): 685-96. DOI: 10.1056/NEJMoa065368 PMID: 17301299
5. Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, et al. Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial. Vaccine. 2015; 33(4): 535-41. DOI: 10.1016/j.vaccine.2014.11.044 PMID: 25488331
6. Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015; 16(5): 471-88. DOI: 10.1007/s10198-014-0586-4 PMID: 24859492
7. Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine. 2006; 24(23): 4934-41. DOI: 10.1016/j. vaccine.2006.03.057 PMID: 16678945
8. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016; 21(38).
9. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016; 21(38).
10. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in Europe. Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013-14 and 2014-15 influenza seasons. Stockholm: ECDC. 2016. Available from: http://ecdc. europa.eu/en/publications/publications/seasonal-influenzavaccination- antiviral-use-europe.pdf
11. Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on the use of nasal spray flu vaccine for the childhood influenza immunisation programme. Aug 2016. Available from: https://www.gov.uk/government/uploads/ system/uploads/attachment_data/file/548515/JCVI_statement. pdf
12. Westreich D, Hudgens MG. Invited Commentary: Beware the Test-Negative Design. Am J Epidemiol. 2016; 184(5): 354-6. DOI: 10.1093/aje/kww063 PMID: 27587722
13. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol. 2016; 184(5): 345-53. DOI: 10.1093/aje/kww064 PMID: 27587721
14. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014; 13(12): 1571-91. DOI: 10.1586/14760584.2014.966695 PMID: 25348015
15. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill. 2013; 18(37): 20585. DOI: 10.2807/1560-7917.ES2013.18.37.20585 PMID: 24079398
16. Foppa IM, Ferdinands JM, Chaves SS, Haber MJ, Reynolds SB, Flannery B, et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol. 2016;dyw022.PMID: 26979985
17. U.S. Food & Drug Administration (FDA). FDA Information Regarding FluMist Quadrivalent Vaccine. Silver Spring: FDA. [Accessed 8 Sep 2016]. Available from: http://www.fda. gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm508761.htm
18. Centers for Disease Control and Prevention (CDC). ACIP votes down use of LAIV for 2016-2017 flu season. Atlanta: CDC. 22 Jun 2016. Available from: http://www.cdc.gov/media/ releases/2016/s0622-laiv-flu.html
19. European Medicines Agency (EMA). Guideline on influenza vaccines. Non-clinical and clinical module. Draft. London: EMA. 15 Jul 2014. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2014/07/ WC500170300.pdf
20. Valenciano M, Ciancio B, I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill. 2012; 17(39): 20281. PMID: 23041022
21. Innovative Medicines Initiative (IMI). Calls for proposals. IMI 2 - Call 9. Brussels: IMI. [Accessed 20 Sep 2016]. Available from: http://www.imi.europa.eu/sites/default/files/uploads/ documents/IMI2Call9/IMI2_Call9_TopicsText.pdf
22. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013; 10(10): e1001527. DOI: 10.1371/ journal.pmed.1001527 PMID: 24115913